Mutations induced at CpG sites require DNMT1, whereas mutations at non-CpG sites do not. (A) Schematic of the GEMINI Assay used for in-vitro drug treatment and subsequent WES. (B) Total mutations induced in each treatment group. Unequal variances t test (1 tailed). (C) C>G, C>T, and C>A mutations induced at CpG sites and non-CpG sites. Unequal variances t test (1-tailed); ∗, P < .05; ∗∗, P < .01; ∗∗∗, P < .001; ns, not significant.